Filters
Treatment with ixekizumab (IXE) for moderate-to-severe plaque psoriasis is consistently safe and effective through 264 weeks in patients using the approved dose, according to the UNCOVER-3 study.
New drug applications approved by US FDA as of 16-31 July 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Patients with psoriasis taking the immunosuppressant methotrexate had low antibody responses to SARS-CoV-2 after receiving the first dose of Pfizer-BioNTech’s BNT162b2 vaccine but had shown T-cell responses, according to a study that was the first to look at T-cell responses in patients taking methotrexate.
Bimekizumab appeared to be more effective than secukinumab in improving skin clearance in patients with moderate-to-severe plaque psoriasis, according to the multinational, phase IIIb BE RADIANT trial presented at AAD 2021.
Use of the highly selective oral Bruton’s tyrosine kinase inhibitor tirabrutinib appears effective in the treatment of patients with refractory pemphigus, inducing remission and cutting oral corticosteroid use without major safety concerns, according to data from a phase II trial.
A short interval as compared to a long one between the primary melanoma excision and obtaining a sentinel lymph node biopsy specimen demonstrate similar patient outcomes, reports a recent study.
A systematic review and network meta-analysis of studies assessing small molecule inhibitors and biologic drugs show that tofacitinib and ixekizumab are the most effective treatments for nail psoriasis in 10 to 16 weeks and 24 to 26 weeks, respectively.
Low-dose skin electron beam therapy using a rotational technique demonstrates a very high overall response rate and an improvement in skin-related quality of life (QOL) in patients with mycosis fungoides, the most common form of cutaneous T-cell lymphoma, reports a recent study.
Topical terbinafine 10% solution (MOB-015) is a viable option for the treatment of mild-to-moderate distal subungual onychomycosis, with an adverse event profile similar to vehicle, suggests a study.
The increasing use of social media and online reviews has made it easier for patients to comment publicly—on Facebook and Google reviews, for instance—on the care they receive. Positive comments are heartening for any healthcare professional to read.
